Literature DB >> 24522700

NK cells after transplantation: friend or foe.

Uzi Hadad1, Olivia Martinez, Sheri M Krams.   

Abstract

Natural killer (NK) cells are effector cells of the innate immune system that can lyse target cells without prior sensitization and have an important role in host defense to pathogens and transformed cells. A balance between negative and positive signals transmitted via germ line-encoded inhibitory and activating receptors controls the function of NK cells. Although the concept of "missing-self" would suggest that NK cells could target foreign allografts, the prevailing dogma has been that NK cells are not active participants in the mechanisms that culminate in the rejection of solid organ allografts. Recent studies, however, challenge this conclusion and instead implicate NK cells in contributing to both graft rejection and tolerance to an allograft. In this review, we highlight recent studies with the goal of understanding the complex NK cell interactions that impact alloimmunity.

Entities:  

Mesh:

Year:  2014        PMID: 24522700     DOI: 10.1007/s12026-014-8493-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  114 in total

Review 1.  Ligands for natural killer cell receptors: redundancy or specificity.

Authors:  A Cerwenka; L L Lanier
Journal:  Immunol Rev       Date:  2001-06       Impact factor: 12.988

2.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

3.  Natural killer cell signaling pathways.

Authors:  Eric Vivier; Jacques A Nunès; Frédéric Vély
Journal:  Science       Date:  2004-11-26       Impact factor: 47.728

4.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  Activation of intragraft endothelial and mononuclear cells during discordant xenograft rejection.

Authors:  M L Blakely; W J Van der Werf; M C Berndt; A P Dalmasso; F H Bach; W W Hancock
Journal:  Transplantation       Date:  1994-11-27       Impact factor: 4.939

6.  NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1.

Authors:  Claudia Semino; Giovanna Angelini; Alessandro Poggi; Anna Rubartelli
Journal:  Blood       Date:  2005-03-31       Impact factor: 22.113

7.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

8.  NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.

Authors:  Monia Draghi; Achal Pashine; Bharati Sanjanwala; Ketevan Gendzekhadze; Claudia Cantoni; David Cosman; Alessandro Moretta; Nicholas M Valiante; Peter Parham
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

9.  Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts.

Authors:  Lori K Phillips; Elizabeth A Gould; Harish Babu; Sheri M Krams; Theo D Palmer; Olivia M Martinez
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

10.  Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.

Authors:  Lu-En Wai; Masato Fujiki; Saori Takeda; Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2008-01-15       Impact factor: 4.939

View more
  15 in total

Review 1.  Immunological aspects of liver cell transplantation.

Authors:  Felix Oldhafer; Michael Bock; Christine S Falk; Florian W R Vondran
Journal:  World J Transplant       Date:  2016-03-24

2.  Differential role of natural killer group 2D in recognition and cytotoxicity of hepatocyte-like cells derived from embryonic stem cells and induced pluripotent stem cells.

Authors:  Trinidad Cisneros; Danielle W Dillard; Xiumei Qu; Justin Arredondo-Guerrero; Martha Castro; Steven Schaffert; Renata Martin; Carlos O Esquivel; Sheri M Krams; Olivia M Martinez
Journal:  Am J Transplant       Date:  2019-01-16       Impact factor: 8.086

3.  NK Cells of Kidney Transplant Recipients Display an Activated Phenotype that Is Influenced by Immunosuppression and Pathological Staging.

Authors:  Ulrike Hoffmann; Christine Neudörfl; Kerstin Daemen; Jana Keil; Maja Stevanovic-Meyer; Frank Lehner; Hermann Haller; Cornelia Blume; Christine S Falk
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

4.  Broad Impairment of Natural Killer Cells from Operationally Tolerant Kidney Transplanted Patients.

Authors:  Emilie Dugast; Gaëlle David; Romain Oger; Richard Danger; Jean-Paul Judor; Katia Gagne; Mélanie Chesneau; Nicolas Degauque; Jean-Paul Soulillou; Pascale Paul; Christophe Picard; Pierrick Guerif; Sophie Conchon; Magali Giral; Nadine Gervois; Christelle Retière; Sophie Brouard
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

5.  Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function.

Authors:  John P Veluchamy; María Delso-Vallejo; Nina Kok; Fenna Bohme; Ruth Seggewiss-Bernhardt; Hans J van der Vliet; Tanja D de Gruijl; Volker Huppert; Jan Spanholtz
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

6.  Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions in vitro.

Authors:  Amandine Pradier; Maria Papaserafeim; Ning Li; Anke Rietveld; Charlotte Kaestel; Lyssia Gruaz; Cédric Vonarburg; Rolf Spirig; Gisella L Puga Yung; Jörg D Seebach
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

7.  Standardisation of flow cytometry for whole blood immunophenotyping of islet transplant and transplant clinical trial recipients.

Authors:  Elvira Jimenez Vera; Yi Vee Chew; Leigh Nicholson; Heather Burns; Patricia Anderson; Hsiao-Ting Chen; Lindy Williams; Karen Keung; Negar Talaei Zanjani; Suat Dervish; Ellis Patrick; Xin Maggie Wang; Shounan Yi; Wayne Hawthorne; Stephen Alexander; Philip J O'Connell; Min Hu
Journal:  PLoS One       Date:  2019-05-22       Impact factor: 3.240

Review 8.  Natural Killer Cells in Kidney Health and Disease.

Authors:  Jan-Eric Turner; Constantin Rickassel; Helen Healy; Andrew J Kassianos
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

9.  Augmentation of Recipient Adaptive Alloimmunity by Donor Passenger Lymphocytes within the Transplant.

Authors:  Ines G Harper; Jason M Ali; Simon J F Harper; Elizabeth Wlodek; Jawaher Alsughayyir; Margaret C Negus; M Saeed Qureshi; Reza Motalleb-Zadeh; Kourosh Saeb-Parsy; Eleanor M Bolton; J Andrew Bradley; Menna R Clatworthy; Thomas M Conlon; Gavin J Pettigrew
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

10.  Immune Profiles to Predict Response to Desensitization Therapy in Highly HLA-Sensitized Kidney Transplant Candidates.

Authors:  Julie M Yabu; Janet C Siebert; Holden T Maecker
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.